Seres Therapeutics (MCRB) Return on Equity: 2016-2025
Historic Return on Equity for Seres Therapeutics (MCRB) over the last 10 years, with Sep 2025 value amounting to -2.64%.
- Seres Therapeutics' Return on Equity rose 114.00% to -2.64% in Q3 2025 from the same period last year, while for Sep 2025 it was -2.64%, marking a year-over-year increase of 114.00%. This contributed to the annual value of -8.10% for FY2024, which is 362.00% down from last year.
- According to the latest figures from Q3 2025, Seres Therapeutics' Return on Equity is -2.64%, which was down 282.18% from 1.45% recorded in Q2 2025.
- Seres Therapeutics' Return on Equity's 5-year high stood at 10.68% during Q1 2023, with a 5-year trough of -8.67% in Q3 2023.
- Its 3-year average for Return on Equity is 1.14%, with a median of 1.23% in 2023.
- Per our database at Business Quant, Seres Therapeutics' Return on Equity spiked by 1,149bps in 2023 and then crashed by 1,121bps in 2024.
- Seres Therapeutics' Return on Equity (Quarterly) stood at -0.42% in 2021, then tumbled by 425bps to -4.67% in 2022, then skyrocketed by 589bps to 1.23% in 2023, then spiked by 395bps to 5.17% in 2024, then surged by 114bps to -2.64% in 2025.
- Its last three reported values are -2.64% in Q3 2025, 1.45% for Q2 2025, and 2.43% during Q1 2025.